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Abstract
In the rodent, epithelial end buds define the tips of elongating
mammary ducts. These highly motile structures undergo repeated
dichotomous branching as they aggressively advance through fatty
stroma and, turning to avoid other ducts, they finally cease growth
leaving behind the open, tree-like framework on which secretory
alveoli develop during pregnancy. This review identifies the motility
of end buds as a unique developmental marker that represents the
successful integration of systemic and local mammotrophic
influences, and covers relevant advances in ductal growth
regulation, extracellular matrix (ECM) remodeling, and cell adhesion
in the inner end bud. An unexpected growth-promoting synergy
between insulin-like growth factor-1 and progesterone, in which
ducts elongate without forming new end buds, is described as well
as evidence strongly supporting self-inhibition of ductal elongation
by end-bud-secreted transforming growth factor-β acting on
stromal targets. The influence of the matrix metalloproteinase ECM-
remodeling enzymes, notably matrix metalloproteinase-2, on end
bud growth is discussed in the broader context of enzymes that
regulate the polysaccharide-rich glycosaminoglycan elements of
the ECM. Finally, a critical, motility-enabling role for the cellular
architecture of the end bud is identified and the contribution of
cadherins, the netrin/neogenin system, and ErbB2 to the structure
and motility of end buds is discussed.
Introduction
The mammary gland develops in two structurally and
functionally distinct phases: ductal and secretory. In the
ductal phase a branched ‘tree’ arises as the epithelial mammary
anlagen invades fatty stroma and, between parturition and
adolescence, undergoes repeated dichotomous branching,
creating the tubes that deliver milk to the nipple (Fig. 1a). The
resulting ‘open’ ductal architecture permits infilling of the
interductal stroma by secretory alveoli during the second
phase of development initiated by pregnancy. The open
mammary duct system is unique in comparison with other
branched organs such as the lung and kidney, whose
epithelial elements are tightly packed.
As we will discuss in this review, the development of the
mammary ductal tree presents fascinating and challenging
problems to the developmental biologist. Beyond this, there is
a true urgency to improve understanding of ductal growth
because 90% or more of human mammary cancers are ductal
in origin. The mammary end bud is the icon of the ductal
phase of mammary development in the rodent, at one and the
same time the most familiar and the most mysterious of
structures. Terminal end buds are familiar in rodents as the
bulbous, epithelial structures at the tips of ducts strategically
located facing an open expanse of fat pad (Fig. 1a, top
arrows). This location and their sensitivity to mammotrophic
hormones such as estrogen and growth hormone (GH)
marked them early on as the engines of ductal elongation,
and their implied motility was understood to be the basis for
the open architecture of the mammary ductal system [1,2]. In
contrast, lateral buds develop along mature ducts and are
constrained in growth by the lack of open territory (Fig. 1a,
side arrow). Apart from location, the general architecture and
function of terminal and lateral end buds are the same.
End buds, like the ducts they give rise to, have a ‘tube within
a tube’ structure with an outer layer of undifferentiated cap
cells and inner layers of luminal epithelial cells (Fig. 1b); both
layers of the end bud have high rates of mitosis, consistent
with a motile organ dedicated to ductal morphogenesis
(Fig. 2) [3]. From these and other studies, forward extension
rates in end buds of up to 0.5 mm per day have been
estimated during maximal growth in puberty (GB Silberstein
and CW Daniel, unpublished data). The purpose of this
review is threefold: first, to draw attention to complex ‘motility
behaviors’ in end buds, such as bifurcation, turning, and
growth cessation; second, to revisit ductal morphogenesis
and epithelial stromal interactions from the point of view of
the end bud; and third, to review the mechanisms mediating
adhesion between cells within the end bud and their crucial
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role in organizing forward movement. We will first address
recent advances in our understanding of ductal growth
regulation, then consider extracellular matrix (ECM)
remodeling, and conclude with a consideration of the
molecular mechanisms that ensure the integrity of the internal
layers of the end bud as it moves through the fat pad.
End bud motility
The mystery of the end bud has always been in the details of
its motility. Over the past decade these have begun to come
into focus and are now known to encompass endocrine and
local growth-regulatory signals, stromal–epithelial inter-
actions, ECM remodeling, and dynamic adhesions within the
end bud that maintain the bilayered structure. Relatively
recent reviews have addressed the growth and morpho-
genesis of the end bud as part of the broader picture of
postnatal mammary development without focusing on motility
itself [4,5]. In the absence of real-time photographic
evidence, the motility of end buds has always been inferred
from static photomicrographs. To demonstrate the complexity
of end bud motility experimentally, we surgically placed a
plastic obstacle into the fat pad of a mouse in the path of
advancing end buds a week before killing (Fig. 1a, asterisk).
The resulting branching pattern of two affected ducts
(dashed lines) illustrates how a combination of end bud
forward movement, avoidance of nearby obstacles, and
bifurcation was adapted to achieve open architecture. End
bud array no. 1 arose from an end bud that grew around the
obstacle and then bifurcated twice; array no. 2 arose from an
end bud that passed beneath the plastic, sending two lateral
branches upward before leaving the proximity of the plastic
and twice bifurcating. Despite the obstacle, therefore, end
bud motility achieved ductal spacing similar to the unaffected
part of the gland. While these types of behavior can be
inferred by experiments such as these, the development of
methods in vitro to culture mammary explants containing end
buds such that extending end buds could be imaged in real
time would constitute a major advance.
Figure 1
Photomicrographs illustrating motility and histoarchitecture of end buds. (a) Natural and experimentally induced motility ‘behavior’ of end buds in
the mammary ductal system of a 5-week-old nulliparous mouse. The ‘open’ ductal architecture of the mammary tree leaves 80% or more of the
gland epithelium-free. Large terminal end buds identify the most actively growing region of the gland (top arrows), and progressively smaller lateral
end buds extend to each side of the center, indicating slowed forward growth as the end bud encounters a thinning fat pad. End buds may also
reverse direction to grow back into accommodating stroma (side arrow). Bifurcating end buds (top arrows) are arrayed along the growth front.
Original magnification approx. ×12. (b) Cross-section through end bud with accompanying diagram. End buds are bilayered structures; an outer
layer of myoepithelial progenitor cells (cap cells) overlays a multilayered mass of luminal cells fated to form the walls of the ductal lumen (L).
Stained with hematoxylin and eosin. Original magnification approx. ×300.
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Growth stimulation and motility of end buds
Although motility clearly includes subtle ‘behaviors’ such as
turning and bifurcation, the crucial consideration is forward
movement. In broad terms this could be due to two
mechanisms: end buds pulling themselves forward by cellular
extensions such as filopodia, or pushing forward due to
mitosis and an increase in cell mass. Electron microscopy
studies show the imprints of adipocytes compressed onto an
unbroken basal lamina covering the tip of the end bud [3].
This, and the absence of filopodia that might pull the duct
forward or any evidence of enzymatic ‘clearing’ of a stromal
path, indicates that forward movement of the end bud must
depend on channeling the internal force of dividing cells in a
forward direction. Motility and ductal growth of the end bud
are therefore synonymous and must be wholly explainable by
the balance of positive and negative growth regulation.
The endocrine hormones estrogen and GH were the only
known ductal mammogens until genetically engineered mice
lacking ovarian hormone receptors or specific growth
factors enabled crucial experiments demonstrating that
these hormones did not act directly on the duct, but rather
through stroma-derived growth factors (reviewed in [5]). In
seminal experiments, Cuhna and colleagues co-
transplanted estrogen receptor knockout (ERKO) mammary
epithelium with wild-type mammary stroma and discovered
that stromal, not epithelial, estrogen receptors were
necessary for ductal development; estrogen therefore
stimulated ductal growth through secondary, paracrine
effectors [6]. EGF can substitute for estrogen in stimulating
end bud growth and was a candidate estrogen
intermediary; however, when EGF receptor knockout
mammary tissue was used in epithelial–stromal co-
transplant experiments, EGF receptor-null stroma could not
support ductal growth by wild-type epithelium. Estrogen-
stimulated stromal EGF must therefore generate other
stromal mammogens whose identity is unknown [7].
During the same period as the estrogen-centered investiga-
tions, evidence was developed by the Kleinberg group that
GH also stimulated end bud growth through a stromal
intermediary, in this case insulin-like growth factor-1 (IGF-1).
In hypophysectomized mice, exogenous GH stimulated
stromal, not epithelial, IGF-1 mRNA expression, and a
targeted deletion of IGF-1 ablated end buds that could then
be restored by exogenous IGF-1 but not by GH [8,9]. The
stimulatory effects of both estrogen and GH on end buds
with each hormone acting through a different stromal
intermediary suggested that the two pathways might
normally synergize. Synergy was in fact demonstrated by
Ruan and colleagues with ovariectomized, IGF-1-knockout
mice supplemented with IGF-1 alone or in combination with
estrogen; the combined treatments stimulated significant
end bud development, whereas estrogen alone was not
stimulatory [10]. Interestingly, the pathway governing end
bud bifurcation may also be linked to IGF-1 because
branching, but not elongation, was reduced in IGF-1-
deficient (IGF-1m/m) mammary glands [11]. The effect of
progesterone on ductal growth was also investigated in the
IGF-1-null model with surprising and important results [10].
As with estrogen, progesterone alone had no effect on end
bud development in ovariectomized mice. In combination
with IGF-1, however, progesterone stimulated ductal
elongation and branching equivalent to that seen with IGF-1
plus estrogen, but without an increase in the number of end
buds. The finding that progesterone can have a role in ductal
elongation in the mouse mammary gland could help to
explain very rapid ductal development in puberty when
estrous-cycle progesterone and estrogen could act together
to optimize growth.
Available online http://breast-cancer-research.com/content/7/6/245
Figure 2
Photomicrograph of a longitudinal section through an end bud and its
subtending duct. A lateral end bud stained to reveal sulfated
glycosaminoglycans and mitotic cells with the cap cell layer is
indicated by the dashed line. Constriction of the end bud to ductal
dimensions coincides with induction of a collagenous extracellular
matrix along the end bud flank. Note that this sheath is continuous with
the subtending duct as well as the duct of origin (dotted lines). The
basal lamina along the end bud flank (large arrows) as well as in the
cleft of a bifurcation (triangle) stained deeply for sulfated
glycosaminoglycans (Alcian blue stain). This contrasts with weakly
stained basal lamina around the end bud tip indicative of non-sulfated
hyaluronate (short arrows). Silver grains (dark spots) are from tritiated
thymidine autoradiography and mark mitotic cells in the end bud and
subjacent ducts. Original magnification approx. ×300.
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Inhibiting ductal elongation: the case for
transforming growth factor-β
The mammary stroma strongly promotes ductal growth; the
smallest fragment of duct transplanted anywhere within an
epithelium-free fat pad vigorously grows into a full ductal tree
[12]. Logic dictates that if the stromal background is growth-
promoting, then achieving patterned growth requires ducts to
adjust their own extension locally by focal inhibition. Strong
evidence now implicates transforming growth factor-β
(TGF-β) as the primary local inhibitor of both ductal
elongation and lateral branching. The inhibition of lateral
branching by TGF-β secreted by ductal epithelium and acting
on periductal stromal targets has been well documented and
can account, in part, for the open architecture of the gland
(reviewed in [4]). More recently, epithelial TGF-β was also
shown to inhibit the forward movement of terminal end buds.
In wild-type mammary glands, activated TGF-β was localized
in the end bud by IHC; when this expression was reduced
through engineered heterozygosity (TGF-β+/– epithelium),
ductal elongation into wild-type stroma was accelerated [13].
Expression of a dominant-negative, TGF-β type-II receptor in
the mammary stroma also caused accelerated ductal growth
during puberty, confirming the stromal target for TGF-β [14].
The above results demonstrate that TGF-β must limit ductal
elongation through secondary effectors, and a case can be
made that these unknown factors act by inhibiting hepatocyte
growth factor. Mammary hepatocyte growth factor is
negatively regulated by TGF-β and its overexpression in
retrovirally transduced mouse mammary epithelial cells
resulted not only in increased lateral branching but also in a
marked increase in the number and size of end buds [15]. A
role for parathyroid hormone-related protein must also be
considered in this context because it is positively regulated
by TGF-β and inhibits ductal elongation when overexpressed
in pubertal mice [16]. Collectively, these findings place the
inhibition of each type of ductal extension, lateral branches
and end buds, under what may be a common, TGF-β-
dependent, circuit. This has two interesting implications. First,
ductal growth stimulation, whether lateral branching or end
bud extension, probably shares mechanisms designed to
inhibit TGF-β action locally, possibly by modulating the
activation of latent growth factor. Second, the inhibition
observed when an end bud approaches the edge of the fat
pad or another duct is likely to come from the advancing end
bud itself and not, as speculated in earlier reviews, from
nearby tissues [5].
These recent studies build on a history of research in which
genetically modified mammary epithelium and stroma are
recombined with wild-type counterparts in all permutations to
evaluate potential ductal mammogens and also to define
whether their primary site of action is the epithelium or
stroma. In this way, stromal sites of action for TGF-β,
parathyroid hormone releasing protein as well as estrogen
and EGF receptors have been defined (reviewed in [17]).
Although these recombination experiments are powerful, they
cannot define the action of particular stromal cells because
they use an intact fat pad. The histologically complex fat pad
comprises many cell types, not just adipocytes and
fibroblasts but also endothelial and migratory white blood
cells, all of which influence the dynamic ECM. A new and very
creative generation of experiments has begun to address this
subtlety by focusing on individual stromal components. For
example, a role for eosinophils and macrophages in end bud
growth has been identified by the ablation of white blood
cells with radiation [18]. In addition, a novel transplant system
that combines purified mouse fibroblasts with mammary
epithelium will enable the testing of specific fibroblast
mutations on ductal growth [17]. The ultimate challenge,
then, will be to relate findings from these experiments to
mechanisms controlling the cell proliferation driving end bud
extension and to identify putative motility factors that affect
turning and bifurcation.
End bud ‘behaviors’ and ECM remodeling
The forward movement of an end bud is inseparable from the
drastic remodeling of the ECM that occurs along its flank
(Fig. 2). There, the induction of sulfated glycosaminoglycans
(SGAGs) in the basal lamina is accompanied by thickening of
the ECM by type I collagen [19]. Because these changes
coincide with the constriction of the end bud to ductal
dimensions it seems likely that the relatively inelastic ECM
girdle ultimately channels the pressure developed by cell
division within the end bud forward, where no type I collagen
constrains expansion. This model could also account, in part,
for end bud bifurcation, in which focal induction of SGAGs in
the end bud basal lamina, followed by the deposition of type I
collagen, retards advancement at the induction point. To
either side of focal type-1 collagen induction, newly formed
lobes advance in different directions (Fig. 2). Although
speculative, the turning of an end bud could depend on
asymmetric deposition and remodeling of SGAG and type I
collagen; collagen deposition on one side of an end bud
might channel extension in the opposite direction. A possible
role for asymmetric mitosis as a turning mechanism has also
been considered; however, when mitotic patterns were
examined with the use of thymidine autoradiography no
obvious correlations between mitosis and turning were found
(GB Silberstein and CW Daniel, unpublished data).
The molecular mechanisms that affect ECM remodeling
around the end bud are coming into focus and fall broadly
into two categories: ECM-active growth factors and matrix-
modifying enzymes. TGF-β1 remains the primary candidate
for inducing the matrix remodeling described above. It is well
known for its ‘matrix sparing’ activity because it inhibits
matrix-degrading proteases and induces SGAGs and other
matrix elements. When TGF-β was delivered by slow-release
implants in the vicinity of end buds, it induced SGAG and
type I collagen around end bud tips that was
indistinguishable from that seen on the flank [4,20].
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Research to understand the role of ECM-remodeling
enzymes in the motility of end buds is in its infancy. In
addition to proteinases, such as the matrix metalloproteinases
(MMPs), matrix glycosaminoglycan (GAG)-degrading glycolytic
enzymes (for example β-glucuronidase) and polysaccharide
synthetases (glycosyltransferases) must also have crucial
functions. MMPs are by far the best studied of the matrix-
remodeling enzymes and comprise a diverse family of stromal
enzymes with overlapping substrates that collectively can
degrade all protein and glycoprotein elements of the ECM
[21]. Inhibition of MMPs by a small-molecule inhibitor
(GM6001) or by transgenic overexpression of a natural MMP
inhibitor, tissue inhibitor of metalloproteinase (TIMP), retarded
the extension of end buds and reduced their total number
[22]. MMP-2 can degrade basal lamina proteins of end buds,
such as type IV collagen and laminin, and can also modulate
the activation of latent TGF-β. MMP-2 is expressed in the
stroma in front of end buds, where it can affect ductal growth
and, indeed, genetic ablation of MMP-2 retarded end bud
extension. Interestingly, this effect was not attributable to a
build-up of undegraded ECM proteins, nor did MMP-2
ablation affect the number of end buds or their cell
proliferation, but rather rates of apoptosis were approximately
doubled, indicating that MMP-2 normally supports cell
survival in the end bud.
The turnover of polysaccharides in the basal lamina and ECM
around the tip of the end bud has been well documented, and
enzymatic degradation of hyaluronate in situ disrupts cellular
organization in the end bud [19,23]. Localization of β-
glucuronidase and N-acetylglucosaminidase by activity staining
in situ with chromogenic substrates revealed strong concen-
trations of these GAG-degrading enzymes in the cap and
myoepithelial cells (GB Silberstein and CW Daniel,
unpublished data). This suggests a role for these and
possibly other glycosidases in basal lamina dynamics and
suggests that further investigation of these enzymes during
ductal extension will be fruitful. Finally, the incorporation of
polysaccharides into elements of the basal lamina–ECM
complex depends on specific glycosyltransferases. Although
nothing is currently known about the biosynthetic roles of
these enzymes in ECM dynamics in the mammary gland, the
fact that they that can also serve as cell-surface receptors for
ECM carbohydrate substrates is intriguing. Mice lacking cell-
surface β1,4-galactosyltransferase, for example, exhibited
increased branching accompanied by perturbation of laminin
and the expression of certain MMPs [24].
Dynamic integrity: adhesion within the end bud
In addition to growth regulation and ECM remodeling, end
bud motility and ductal outgrowth rely on the integrity of the
end bud because perturbations that disrupt cell adhesion
within an end bud inhibit ductal extension. There are at least
two examples in the literature of different ways in which
disorganized end bud structure can compromise forward
growth. In one example, the disruption of cell–cell contacts
within an end bud inhibited cell proliferation and ductal
extension, suggesting that normal cell contacts are required
to mediate the growth signals from mammogenic hormones
such as estrogen and GH. In two other examples, disruption
of cell–cell contacts inhibited forward growth independently
of cell proliferation, suggesting that additional mechanisms,
involving tissue integrity, also control end bud outgrowth.
Together these examples highlight the idea that, in addition to
the essential relay of information that occurs between the
epithelial and stromal compartments, proper communication
between cells within the epithelium is crucial for normal
ductal development.
One of the first examples demonstrating the essential nature
of proper cell–cell contacts involved the perturbation of
cadherin function. Cadherins are calcium-dependent cell
adhesion proteins that mediate interactions between cells of
the end bud. At least two types of cadherin are expressed in
the end bud: E-cadherin (Cdh1) is expressed by luminal cells
that constitute the body of the end bud, and P-cadherin
(Cdh3) is expressed by cap cells that form the outer layer
(Fig. 3) [25]. Because homozygous mutations in the Cdh1
gene resulted in early embryonic lethality, functional studies
were performed by surgically inserting slow-release implants
containing function-blocking antibodies ahead of advancing
end buds. Within 12 hours of implantation, luminal cells in the
body of the end bud exhibited disrupted cell–cell adhesion
and epithelial DNA synthesis abruptly declined. After
72 hours the function-blocking antibodies were depleted,
leading to the restoration of normal tissue morphology and
recovered rates of DNA synthesis. These results showed that
normal cell contacts are required for the maintenance of
tissue architecture. Moreover, these experiments demon-
strated that the high rates of DNA synthesis responsible for
driving cell proliferation rely on cadherin-mediated cell–cell
contacts. The authors also used function-blocking antibodies
directed against CDH3 [25]. Interestingly, this treatment
resulted in only a modest disruption in the cap cell layer of the
end bud that was accompanied by only a slight decline in
DNA synthesis. Studies on genetically engineered mice
lacking Cdh3 yielded a similar result by showing that loss of
CDH3 had no discernible affect on ductal outgrowth or
branching morphogenesis [26]. Together, these results
suggest that tissue integrity is required for epithelial
proliferation, but modest perturbations in end bud structure
can be accommodated.
Although CDH1 and CDH3 mediate interactions between
cells of the luminal and cap cell compartments, respectively,
recent data suggest that Netrin-1 (Ntn1) mediates
interactions between these two compartments. NTN1 was
originally identified as a guidance cue for developing neurons
[27], but in the mammary gland this cue seems to function
adhesively at short range, rather than instructively at long
range [28]. NTN1 is expressed by luminal cells [28]; although
a secreted protein, it is not freely diffusible but is instead
Available online http://breast-cancer-research.com/content/7/6/245
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immobilized in association with cell membranes or compo-
nents of the ECM [29]. The NTN1 receptor, Neogenin
(Neo1), is expressed in a complementary pattern by overlying
cap cells [28]. Glands harboring homozygous loss-of-function
mutations in either gene displayed slower growth that
corresponded to significantly disorganized end buds [28].
These growth structures exhibited loss of adhesion between
the cap and luminal cell layers, with large spaces forming
under the cap cell layer (Fig. 3). These spaces filled with
dissociated cap cells that either died by apoptosis or
migrated inappropriately either into the body of the end bud
or into the stromal compartment. Rates of DNA synthesis in
mutant and wild-type glands were similar, suggesting that
disrupting contacts between the cap and luminal cell layers
inhibited mammary outgrowth by elevating cell death, not by
inhibiting cell proliferation. These data suggest that NTN1,
signaling though NEO1, maintains the integrity of the end
bud by mediating contacts between cap and luminal epithelial
cells, and these contacts are required for robust forward
growth of the mammary tree.
A second example demonstrating that disruption of cell–cell
contacts inhibits forward growth, independently of cell
proliferation, is in glands harboring homozygous loss-of-
function mutations in Erbb2. ERBB2 is an orphan receptor
that forms heteromers with ligand-activated EGFR, ERBB3,
and ERBB4, allowing it to respond to EGF and neuregulin-
like growth factors. In Erbb2–/– mammary glands, there was a
marked reduction in ductal outgrowth into the mammary fat
pad that was accompanied by increased lateral branching
[30]. There were no apparent changes in cell proliferation or
apoptosis to account for this lack of mammary outgrowth; it
therefore seemed that lateral branching occurred at the
expense of forward penetration of the end bud into the fat
pad [30]. Because end buds are the structure responsible for
generating forward growth, the authors examined end bud
structure and discovered that Erbb2–/– end buds were small
and disorganized. Although they had a normal cap cell layer,
exaggerated spaces developed between the cap and luminal
cell layers. The small number of luminal cells present in the
bodies of end buds were loosely packed and seemed
disorganized, probably as a result of the inappropriate influx
of cap cells into this compartment. The apparent phenotypic
similarities between Erbb2–/–, Ntn1–/–, and Neo1–/– glands
suggested that loss of ERBB2 leads to downregulation of
NTN1 or NEO1, but expression of these proteins seemed
normal in Erbb2–/– glands [30]. Taken together, these results
suggest that multiple pathways regulate adhesion between
cap and luminal epithelial cells, and that disrupting the
integrity of these layers severely compromises forward
growth of the mammary tree.
Thus, numerous signaling pathways must interact to drive and
channel the forward growth and motility of end buds and this,
in turn, is responsible for establishing the primary structure of
the mammary tree. Although mammogenic hormones
stimulate the cell proliferation required to generate enough
epithelial mass to force end buds forward, the examples
above highlight a second requirement. The structural integrity
of the end bud is essential for both receiving mammogenic
growth signals and organizing forward movement of the end
bud into the fat pad. Together these examples demonstrate
how function follows form, and generating a mammary ductal
tree requires proper cell–cell contacts within end buds
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Figure 3
Loss of Ntn1 disorganizes end buds The Ntn1+/+ end bud (top)
displays normal CDH3 staining of the cap cell layer at the tip of the
end bud (delineated by the dashed line). In contrast the Ntn1–/– end
bud (bottom) displays a loss of adhesion between the cap and luminal
cell layers, with a large space forming under the cap cell layer
(delineated by the dashed line). This space fills with dissociated cap
cells (arrows show three examples) that either die by apoptosis or
migrate inappropriately into the body of the end bud. Original
magnification approx. ×300.
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coordinated with integrated epithelial–stromal and epithelial–
ECM communication.
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